# ETCTN Early Drug Development Opportunity Leadership program administrative supplement to Cancer Center Support Grant

> **NIH NIH P30** · WAYNE STATE UNIVERSITY · 2021 · $125,000

## Abstract

This application is being submitted in response to the EDDOP Leadership Program via the mechanism PA-20-
272, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp
Clinical Trial Optional).”
The Karmanos Cancer Institute (KCI), founded in 1943, is a not-for-profit, cancer-only research and patient
care organization in partnership with Wayne State University (WSU) in Michigan. The designation by the NCI
as a Comprehensive Cancer Center was achieved in 1978. KCI operates its wholly-owned, free-standing,
cancer hospital and ambulatory clinics (KCC) in Detroit and in Farmington Hills, a suburban location. As a
member of McLaren Health Care (MHC), a not-for profit health care corporation, KCI is also responsible for
cancer research, quality of care, and cancer care operations in all facilities owned and operated by MHC. Our
catchment area covers 46 of Michigan's 83 counties with a population of 6.7 million people. This catchment
area is home to 95% of our patients, and KCI sees one-third of all new cancer patients in the catchment area.
The Southeast region of our catchment area includes the metropolitan Detroit, defined as a tri-county area
(Wayne, Oakland, Macomb) and home to 3.86 million residents. The city of Detroit is the largest city in the
state (672,000 residents). Detroit is a resource-challenged area, with a median household income of $27,838
and 37.9% of residents living below poverty level, compared to 16.7% in the state of Michigan. The majority of
census tracts in the city of Detroit are medically underserved areas based on HRSA definitions. About 79% of
Detroit residents identify as African American, a group that disproportionately carries KCI catchment area's
cancer burden. In 2018, KCI physicians saw approximately 12,000 new cancer patients (including
approximately 8,000 analytic cases), with approximately 15% representing minority groups. The annual
number of new cancer cases in these 46 counties is approximately 39,000 and has not changed significantly
since 2014. In FY19, our minority accrual to interventional treatment protocols was 24.2%. We have a long
standing scientific and patient care commitment to the African American population of southeastern Michigan,
as exemplified in the broad array of studies focused on molecular, therapeutic, and social disparities. This
application profiles the strengths and successes of our four scientific Programs, Tumor Biology and
Microenvironment (TBM, 01), Molecular Imaging (MI, 02), Molecular Therapeutics (MT, 03), and Population
Studies and Disparities Research (PSDR, 04). The research efforts of these Programs is supported by nine
Shared Resources (Cores), including one developing Core.

## Key facts

- **NIH application ID:** 10363981
- **Project number:** 3P30CA022453-39S1
- **Recipient organization:** WAYNE STATE UNIVERSITY
- **Principal Investigator:** GEROLD BEPLER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $125,000
- **Award type:** 3
- **Project period:** 2021-04-01 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10363981

## Citation

> US National Institutes of Health, RePORTER application 10363981, ETCTN Early Drug Development Opportunity Leadership program administrative supplement to Cancer Center Support Grant (3P30CA022453-39S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10363981. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*